Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
3.520
-0.190 (-5.12%)
Nov 16, 2026, 4:00 PM EST - Market closed
Immuneering Employees
Immuneering had 65 employees as of September 30, 2026. The number of employees increased by 11 or 20.37% compared to the same quarter last year. That makes Immuneering the 33,848th largest employer in the world and 4,436th in the United States.
Employees
65
Change (1Y)
11
Growth (1Y)
20.37%
Revenue / Employee
n/a
Profits / Employee
-$1,023,137
Market Cap
227.97M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 65 | 11 | 20.37% |
| Jun 30, 2026 | 57 | 3 | 5.56% |
| Mar 31, 2026 | 55 | 1 | 1.85% |
| Dec 31, 2025 | 53 | -1 | -1.85% |
| Sep 30, 2025 | 54 | -12 | -18.18% |
| Jun 30, 2025 | 54 | -12 | -18.18% |
| Mar 31, 2025 | 54 | -11 | -16.92% |
| Sep 30, 2024 | 66 | -1 | -1.49% |
| Jun 30, 2024 | 66 | 0 | - |
| Mar 31, 2024 | 65 | -3 | -4.41% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Sep 30, 2023 | 67 | -7 | -9.46% |
| Jun 30, 2023 | 66 | -8 | -10.81% |
| Mar 31, 2023 | 68 | 0 | - |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Sep 30, 2022 | 74 | 38 | 105.56% |
| Jun 30, 2022 | 74 | 40 | 117.65% |
| Mar 31, 2022 | 68 | 36 | 112.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsIMRX News
- 4 days ago - Immuneering plans Phase 2 atebimetinib trial in anaplastic thyroid cancer - TheFly
- 4 days ago - Immuneering to supply atebimetinib for two Astellas pancreatic cancer studies - TheFly
- 4 days ago - Immuneering Transcript: Study update - Transcripts
- 4 days ago - Immuneering Press release: Study update - Filings
- 4 days ago - Immuneering Slides: Study update - Filings
- 4 days ago - Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer - GlobeNewsWire
- 4 days ago - Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients - GlobeNewsWire
- 7 days ago - Immuneering Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts